# Randomized Evaluation of Shenfu Injection to Reduce Myocardial Injury

Study · id `cardio:ct-nct04493840` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04493840](<https://clinicaltrials.gov/study/NCT04493840>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04493840

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 326 participants.

## Technical summary

Registry record NCT04493840. Randomized; triple masking; primary purpose treatment. Start 2020-07-30 (actual); primary completion 2022-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 326 participants (planned count; ClinicalTrials.gov record NCT04493840, source copy `cardio:ctgov-nct04493840-2021-09-10`, retrieved 2026-10-26)
- Started: 2020-07-30 (actual) (ClinicalTrials.gov record NCT04493840, source copy `cardio:ctgov-nct04493840-2021-09-10`, retrieved 2026-10-26)
- Primary completion: 2022-07-31 (anticipated) (ClinicalTrials.gov record NCT04493840, source copy `cardio:ctgov-nct04493840-2021-09-10`, retrieved 2026-10-26)
- Completion: 2022-08-31 (anticipated) (ClinicalTrials.gov record NCT04493840, source copy `cardio:ctgov-nct04493840-2021-09-10`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04493840, source copy `cardio:ctgov-nct04493840-2021-09-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04493840-2021-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Randomized Evaluation of Shenfu Injection to Reduce Myocardial Injury
- Acronym: RESTORE
- Condition: Myocardial Infarction
- Intervention (Drug): Shenfu Injection
- Intervention (Drug): 5% Glucose Injection
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

## Provenance

Content hash: 8f3212a2d54849a862286600113d7c4bfcf223d4c4c3d5ea38ac31e8d7dd47cd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
